Clinical Trial Detail

NCT ID NCT01498445
Title An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

chronic myeloid leukemia

Therapies

Dasatinib + Decitabine

Age Groups: senior adult

No variant requirements are available.